Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset.

Agnoletto C, Corrà F, Minotti L, Baldassari F, Crudele F, Cook WJJ, Di Leva G, d'Adamo AP, Gasparini P, Volinia S.

Cancers (Basel). 2019 Apr 5;11(4). pii: E483. doi: 10.3390/cancers11040483. Review.

2.

miRNAs in bone metastasis.

Cheung DG, Buzzetti M, Di Leva G.

Expert Rev Endocrinol Metab. 2017 Nov;12(6):451-461. doi: 10.1080/17446651.2017.1383893. Epub 2017 Oct 10. Erratum in: Expert Rev Endocrinol Metab. 2017 Nov;12(6):iii.

PMID:
30063434
3.

Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin.

Drusco A, Fadda P, Nigita G, Fassan M, Bottoni A, Gardiman MP, Sacchi D, Calore F, Carosi M, Antenucci A, Casini B, Kelani H, Pescarmona E, Di Leva G, Zanesi N, Berger MS, Croce CM.

EBioMedicine. 2018 Apr;30:105-112. doi: 10.1016/j.ebiom.2018.03.022. Epub 2018 Mar 21.

4.

Loss of miR-204 expression is a key event in melanoma.

Galasso M, Morrison C, Minotti L, Corrà F, Zerbinati C, Agnoletto C, Baldassari F, Fassan M, Bartolazzi A, Vecchione A, Nuovo GJ, Di Leva G, D'Atri S, Alvino E, Previati M, Nickoloff BJ, Croce CM, Volinia S.

Mol Cancer. 2018 Mar 9;17(1):71. doi: 10.1186/s12943-018-0819-8.

5.

Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells.

Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M, Birk DE, Raso C, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM.

J Biol Chem. 2017 Aug 25;292(34):14279. doi: 10.1074/jbc.A117.709062. No abstract available.

6.

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.

Sci Rep. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0.

7.

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Tang H, Leung L, Saturno G, Viros A, Smith D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R.

Nat Commun. 2017 Apr 18;8:14909. doi: 10.1038/ncomms14909. Erratum in: Nat Commun. 2019 Jul 18;10(1):3151.

8.

Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM.

Cancer Cell. 2016 Aug 8;30(2):349-351. doi: 10.1016/j.ccell.2016.07.007. Epub 2016 Aug 8. No abstract available.

9.

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV.

Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.

10.

Repression of Esophageal Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo.

Taccioli C, Garofalo M, Chen H, Jiang Y, Tagliazucchi GM, Di Leva G, Alder H, Fadda P, Middleton J, Smalley KJ, Selmi T, Naidu S, Farber JL, Croce CM, Fong LY.

J Natl Cancer Inst. 2015 Aug 18;107(11). pii: djv220. doi: 10.1093/jnci/djv220. Print 2015 Nov.

11.

Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.

Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, Joshi P, Alder H, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Croce CM.

PLoS One. 2015 Jun 25;10(6):e0131729. doi: 10.1371/journal.pone.0131729. eCollection 2015. No abstract available.

12.

A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.

Jeon YJ, Middleton J, Kim T, Laganà A, Piovan C, Secchiero P, Nuovo GJ, Cui R, Joshi P, Romano G, Di Leva G, Lee BK, Sun HL, Kim Y, Fadda P, Alder H, Garofalo M, Croce CM.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3355-64. doi: 10.1073/pnas.1504630112. Epub 2015 Jun 15. Erratum in: Proc Natl Acad Sci U S A. 2017 Mar 21;114(12 ):E2542.

13.

miRNA clusters as therapeutic targets for hormone-resistant breast cancer.

Di Leva G, Cheung DG, Croce CM.

Expert Rev Endocrinol Metab. 2015;10(6):607-617. Epub 2015 Oct 13.

14.

Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.

Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon R.

J Natl Cancer Inst. 2014 Oct 11;106(12). pii: dju324. doi: 10.1093/jnci/dju324. Print 2014 Dec. Erratum in: J Natl Cancer Inst. 2014 Nov:106(11):dju373doi:10.1093/jnci/dju373. Garzon, Maria Elena Sana Ramiro [Corrected to Garzon, Ramiro and Sana, Maria Elena].

15.

MicroRNA profiles discriminate among colon cancer metastasis.

Drusco A, Nuovo GJ, Zanesi N, Di Leva G, Pichiorri F, Volinia S, Fernandez C, Antenucci A, Costinean S, Bottoni A, Rosito IA, Liu CG, Burch A, Acunzo M, Pekarsky Y, Alder H, Ciardi A, Croce CM.

PLoS One. 2014 Jun 12;9(6):e96670. doi: 10.1371/journal.pone.0096670. eCollection 2014.

16.

Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri.

Folcik VA, Garofalo M, Coleman J, Donegan JJ, Rabbani E, Suster S, Nuovo A, Magro CM, Di Leva G, Nuovo GJ.

Mod Pathol. 2014 Jun;27(6):851-62. doi: 10.1038/modpathol.2013.198. Epub 2013 Nov 15.

17.

MicroRNAs in cancer.

Di Leva G, Garofalo M, Croce CM.

Annu Rev Pathol. 2014;9:287-314. doi: 10.1146/annurev-pathol-012513-104715. Epub 2013 Sep 25. Review.

18.

MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.

Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, Joshi P, Alder H, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Croce CM.

PLoS One. 2013 Jun 21;8(6):e67581. doi: 10.1371/journal.pone.0067581. Print 2013.

19.

The Role of microRNAs in the Tumorigenesis of Ovarian Cancer.

Di Leva G, Croce CM.

Front Oncol. 2013 Jun 13;3:153. doi: 10.3389/fonc.2013.00153. eCollection 2013.

20.

MicroRNAs.

Di Leva G, Croce CM.

Clin Biochem. 2013 Jul;46(10-11):840-1. doi: 10.1016/j.clinbiochem.2013.05.060. No abstract available.

PMID:
23726294
21.

Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.

Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, Marcucci G, Perrotti D, Powell KA, Bratasz A, Garofalo M, Nephew KP, Croce CM.

PLoS Genet. 2013;9(3):e1003311. doi: 10.1371/journal.pgen.1003311. Epub 2013 Mar 7. Erratum in: PLoS Genet. 2013 Apr;9(4). doi:10.1371/annotation/92dfa670-d431-4d68-b70b-706df1f93e46. Ramasamy, Santhanam [corrected to Santhanam, Ramasamy].

22.

miRNA profiling of cancer.

Di Leva G, Croce CM.

Curr Opin Genet Dev. 2013 Feb;23(1):3-11. doi: 10.1016/j.gde.2013.01.004. Epub 2013 Mar 4. Review.

23.

MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation.

Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16570-5. doi: 10.1073/pnas.1207917109. Epub 2012 Sep 24. Erratum in: Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10389.

24.

Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.

Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM.

Mol Oncol. 2012 Aug;6(4):458-72. doi: 10.1016/j.molonc.2012.03.003. Epub 2012 Apr 19.

25.

MicroRNA in cancer: new hopes for antineoplastic chemotherapy.

Di Leva G, Briskin D, Croce CM.

Ups J Med Sci. 2012 May;117(2):202-16. doi: 10.3109/03009734.2012.660551. Epub 2012 Feb 21. Review.

26.

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.

Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM.

Nat Med. 2011 Dec 11;18(1):74-82. doi: 10.1038/nm.2577. Erratum in: Nat Med. 2014 Jan;20(1):103.

27.

MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.

Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP.

Oncogene. 2011 Mar 3;30(9):1082-97. doi: 10.1038/onc.2010.487. Epub 2010 Nov 8.

28.

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM.

Cancer Cell. 2010 Oct 19;18(4):367-81. doi: 10.1016/j.ccr.2010.09.005. Erratum in: Cancer Cell. 2016 Aug 8;30(2):349-351.

29.

Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection.

Nuovo GJ, Wu X, Volinia S, Yan F, di Leva G, Chin N, Nicol AF, Jiang J, Otterson G, Schmittgen TD, Croce C.

Diagn Mol Pathol. 2010 Sep;19(3):135-43. doi: 10.1097/PDM.0b013e3181c4daaa.

30.

Roles of small RNAs in tumor formation.

Di Leva G, Croce CM.

Trends Mol Med. 2010 Jun;16(6):257-67. doi: 10.1016/j.molmed.2010.04.001. Epub 2010 May 20. Review.

31.

Reprogramming of miRNA networks in cancer and leukemia.

Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM.

Genome Res. 2010 May;20(5):589-99. doi: 10.1101/gr.098046.109.

32.

MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.

Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM.

J Natl Cancer Inst. 2010 May 19;102(10):706-21. doi: 10.1093/jnci/djq102. Epub 2010 Apr 13.

33.

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM.

Cancer Cell. 2009 Dec 8;16(6):498-509. doi: 10.1016/j.ccr.2009.10.014.

34.

Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155.

Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, Di Leva G, Ferracin M, Volinia S, Bonmassar E, Croce CM, D'Atri S.

Int J Oncol. 2009 Aug;35(2):393-400.

PMID:
19578755
35.

microRNA-205 regulates HER3 in human breast cancer.

Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E.

Cancer Res. 2009 Mar 15;69(6):2195-200. doi: 10.1158/0008-5472.CAN-08-2920. Epub 2009 Mar 10.

36.

Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells.

Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M, Birk DE, Raso C, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM.

J Biol Chem. 2008 May 16;283(20):13736-44. doi: 10.1074/jbc.M709062200. Epub 2008 Mar 3. Retraction in: J Biol Chem. 2017 Aug 25;292(34):14279.

37.

MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.

Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G.

Oncogene. 2008 Jun 19;27(27):3845-55. doi: 10.1038/onc.2008.6. Epub 2008 Feb 4.

PMID:
18246122
38.

MicroRNA signatures in human ovarian cancer.

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM.

Cancer Res. 2007 Sep 15;67(18):8699-707.

39.

Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer.

Petrocca F, Iliopoulos D, Qin HR, Nicoloso MS, Yendamuri S, Wojcik SE, Shimizu M, Di Leva G, Vecchione A, Trapasso F, Godwin AK, Negrini M, Calin GA, Croce CM.

Cancer Res. 2006 Nov 1;66(21):10287-91.

40.

MicroRNAs: fundamental facts and involvement in human diseases.

Di Leva G, Calin GA, Croce CM.

Birth Defects Res C Embryo Today. 2006 Jun;78(2):180-9. Review.

PMID:
16847883
41.

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM.

N Engl J Med. 2005 Oct 27;353(17):1793-801. Erratum in: N Engl J Med. 2006 Aug 3;355(5):533.

42.

TOP promoter elements control the relative ratio of intron-encoded snoRNA versus spliced mRNA biosynthesis.

de Turris V, Di Leva G, Caldarola S, Loreni F, Amaldi F, Bozzoni I.

J Mol Biol. 2004 Nov 19;344(2):383-94.

PMID:
15522292

Supplemental Content

Loading ...
Support Center